Cop: Fight against the new crown, why monoclonal antibodies are high hopes

recently, the scientific community has high hopes for the role of monoclonal antibodies in the prevention and treatment of new coronavirus infections. Some experts even believe that monoclonal antibody therapy may predation vaccines and play an important role in containing the new crown pandemic., what exactly is monoclonal antibody, and how does it play the role of preventing and treating the new crown?there are no specific drugs for new coronavirus infections. In practice, a treatment idea with better results is plasma therapy, that is, the plasma extracted from the newly crowned rehabilitation is injected into the infected person. The plasma of the recovered person contains antibodies that identify the new coronavirus and can fight the virus in the infected person's body. But this treatment is difficult to apply on a large scale. So the scientists considered identifying specific antibodies in the plasma of the recovered person that can effectively neutralate the new coronavirus, and then mass-produced the antibody by cloning a single cell, which is the monoclonal antibody.monoclonal antibody, also known as a "biological missile," can accurately identify and destroy pathogenic antigens like a missile. Previously, related technologies have played an important role in disease diagnosis, anti-infection and anti-tumor. Today, monoclonal antibodies are also seen as one of the most promising options for combating new coronavirus infections, and research institutions around the world are actively promoting research.the Chinese Academy of Sciences Institute of Microbiology and Shanghai Junshi Biopharmaceutical Technology Co., Ltd. and other units jointly developed the recombinant all-human source anti-neo-coronavirus monoclonal antibody injection was announced in June into phase 1 clinical trials.Researchers such as Chen Wei of the Institute of Military Medicine of the Chinese Academy of Military Sciences, who published a paper online in the American journal Science in June, said they had discovered the first highly effective medium- and monoclonal antibody targeting the N-side domain of the new coronavirus hedgehog protein, providing a new effective target for the development of new crown drugs., British pharmaceutical company AstraZeneta plans to launch a clinical trial of antibody therapy and says it hopes a three-minute monoclonal antibody injection could prevent new coronavirus infections for up to six months.. U.S. drugmaker Lilly announced on August 3rd that it had launched a phase 3 clinical trial of a new coronal antibody therapy to test the effectiveness of a monoclonal antibody developed for viral prickly proteins to prevent new coronary infections. The antibody, called LY-CoV555, was isolated from a blood sample from an early neo-coronary rehabilitation in the United States. In addition, the anti-new crown "cocktail" therapy developed by Regenerative Pharmaceuticals of the United States, consisting of a variety of monoclonal antibodies, has also begun clinical trials.clinical trials of monoclonal antibodies that can prevent and treat new crown infections may be progressing faster than trials related to the new crown vaccine, according to a recent article on the website of the American journal Science. Monoclonal antibodies are expected to act as a "bridge" before the new crown vaccine is available, according to Ajay Nyrula, Lilly's vice president.article also believes that monoclonal antibodies may be more effective than drugs such as Redsivir and dexamisson that can help treat new crowns, not only to protect front-line health care workers from infection, but also to reduce the severity of new crown inpatients. Dennis Burton, an immunologist at the Scripps Institute in the United States, is optimistic that a single injection of monoclonal antibodies will be enough to protect people from new crown infections within months.can play a protective effect, but the vaccine and monoclonal antibodies have different effects. Simply put, a vaccine is an antigen that stimulates the body to produce immunity to act as a preventive action, which is an active immunity, while direct input antibodies are passive immunity that enables the body to obtain immunity immediately, but usually lasts a short period of time and is generally used for treatment or emergency prevention in exceptional circumstances.addition, the use of monoclonal antibodies to treat the new crown also faces cost challenges. Seth Berkeley, chief executive of the Global Alliance for Vaccine Immunization, said: "The price of this treatment is unlikely to fall to globally affordable levels in the near future. Therefore, how to improve the method and reduce the production cost of monoclonal antibodies is also a problem that needs to be solved at this stage. (
.
)